Instrument Inactif

Communiqués Vifor Pharma Deutsche Boerse AG

Actions

G2AA

CH0364749348

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cancellation of remaining publicly held registered shares of Vifor Pharma AG	14/12/22	BU
Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients	28/11/22	BU
Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously	25/11/22	BU
Approval of extension of exemptions from SIX disclosure and publicity obligations	20/10/22	BU
Approval of delisting of Vifor Pharma AG's registered shares	12/10/22	BU
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy	22/08/22	BU
VFMCRP announces U.S. Court upholds validity of Velphoro® patent	22/08/22	BU
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022	19/08/22	BU
VFMCRP - Tavneos (avacopan) recommended by England's NICE for the treatment of AAV (GPA/MPA)	18/08/22	AQ
Tavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)	18/08/22	BU
Finalization of Vifor Pharma acquisition	02/08/22	BU
Vifor Pharma Group - Extension of the postponement of the settlement of Vifor Pharma tender offer	14/07/22	AQ
CSL Limited - Extension of the postponement of the settlement of Vifor Pharma tender offer	13/07/22	AQ
Extension of the postponement of the settlement of Vifor Pharma tender offer	13/07/22	BU
THE EU COMMISSION OPENS ANTITRUST INVESTIGATION INTO COMPETITORS SUSPECTED ILLEGAL DISPARAGEMENT OF PHARMACOSMOS' MAIN INTRAVENOUS IRON PRODUCT	22/06/22	AQ
Update on the timeline for Vifor Pharma tender offer	12/05/22	BU
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients	28/04/22	AQ
94th Vifor Pharma Group Annual General Meeting	26/04/22	BU
DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy	04/04/22	BU
Publication of definitive end result for Vifor Pharma tender offer	28/03/22	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Vifor Pharma Deutsche Boerse AG

Actions

G2AA

CH0364749348

Communiqués

Filtres